Should Shares CRISPR Therapeutics Be a February Pick?
Biotech investors chase game-changing tech, but CRISPR Therapeutics carries real regulatory milestones and execution ...
We evaluate which retirement option—index fund or target date fund—fits your timeline, risk profile, and tax strategy for a smoother retirement.
26,044 articlesBiotech investors chase game-changing tech, but CRISPR Therapeutics carries real regulatory milestones and execution ...
Ripple gains a foothold in the core clearing network as NSCC lists a Ripple-linked entity. The move aligns with Rippl...
The FCC has approved the Nexstar-Tegna deal, creating a national local television powerhouse with 265 stations across...
Qualcomm and Micron lead another leg higher in the AI semiconductor rally, as data center demand and memory tightness...
Hive Digital Technologies stock surged this week thanks to a major AI infrastructure project from its subsidiary. Thi...
A sharp job split shows healthcare added about 900,000 positions while other sectors shed jobs. Investors are reasses...
Rivian shares traded near $14.90 as macro headwinds pressure EV names, while a still-growing VW software venture keep...
Stocks hover near record highs as earnings show resilience, but analysts warn that the gap between prices and profits...
Regulatory clarity stalls on crypto derivatives push on-chain perpetual futures offshore, leading US traders to seek ...
The Doppler token creation platform is extending its reach to Solana, building on its role powering most Base token l...
A private AI company is offering under-$1 pre-IPO shares to everyday investors as it targets a Nasdaq debut later thi...
U.S. stocks push higher into May on AI-driven demand and resilient earnings, with analysts debating whether trump’s b...